B · Normal
On September 21, the head of Novo Nordisk in the United States said that since January, Novo Nordisk’s market share in the field of obesity has increased by about 8 percentage points.
Related telegraphs
[Novo Nordisk responds to "Simeglutide reflux drugs": supports and fully coopera
09-22 11:06
On September 21, Novo Nordisk stated that Mexico is the next market for Wegovy o
09-21 20:59
On September 21, Novo Nordisk’s Chief Scientific Officer (CSO) stated that at le
09-21 16:49
On September 21, the CEO of Novo Nordisk stated that it would launch new innovat
09-21 16:32
On September 21, Novo Nordisk’s CEO stated that by 2030, the company’s productio
09-21 16:28
On September 21, Novo Nordisk’s US stock price fell by more than 7% before the m
09-21 16:12
Comments